Form 4: Arrowhead Pharmaceuticals Director Hongbo Lu Increases Stake in Company

Director Hongbo Lu recently purchased 3,000 shares of Arrowhead Pharmaceuticals, increasing his direct holdings in the company.

Summary

• On March 18, 2024, Hongbo Lu, a director of Arrowhead Pharmaceuticals, purchased 1,000 shares of common stock at a price of $27.49 per share.
• On March 19, 2024, Lu purchased another 1,000 shares at $28 per share.
• On March 20, 2024, Lu purchased an additional 1,000 shares at $27.50 per share.
• Following these transactions, Lu directly owns 33,680 shares of Arrowhead Pharmaceuticals common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. A director buying shares suggests confidence, but the scale of the purchase is not large enough to be overwhelmingly positive.

Positives

• A director increasing their stake in the company can be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Director stock purchases are common and closely watched as indicators of management's sentiment about the company's prospects. These transactions are publicly disclosed to ensure transparency and prevent insider trading.

Stakeholder Impact

• The increased stake of a director could positively influence shareholder confidence.

Key Dates